DFTX vs HELP: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. DFTX and HELP share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined DFTX and HELP exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Definium Therapeutics (Nasdaq: DFTX) is a clinical-stage biopharmaceutical company focused on brain-health and psychiatric disorders. It is the rebranded MindMed, having changed its name from Mind Medicine (MindMed) Inc. in January 2026. Its lead asset is DT120 ODT (formerly MM120), a proprietary orally disintegrating tablet formulation of lysergide (LSD) tartrate being developed for generalized anxiety disorder (GAD) and major depressive disorder (MDD), alongside DT402, an earlier-stage candidate in autism spectrum disorder (ASD). In June 2026 the company reported that its Phase 3 Emerge trial of DT120 in MDD met its primary and key secondary endpoints, and in September 2026 it reported that Panorama, a second Phase 3 trial in GAD, also met its primary endpoint. A pre-NDA meeting with the FDA is scheduled for the fourth quarter of 2026, with an NDA submission planned for the first half of 2027.

Full DFTX guide

Helus Pharma Inc., which began trading on the Nasdaq under the ticker HELP in early 2026 (previously CYBN on NYSE American) and completed its legal name change from Cybin Inc. on October 1, 2026 after shareholders approved it on September 22, is a Toronto-based clinical-stage pharmaceutical company. The ticker did not change, and the shares also trade on Cboe Canada. Its lead program is HLP003 (also referenced as CYB003), a deuterated psilocybin analog with FDA Breakthrough Therapy Designation that is being studied as an adjunctive treatment for major depressive disorder in a registrational Phase 3 program called PARADIGM, which includes the APPROACH and EMBRACE studies. A second candidate, HLP004, a deuterated DMT compound, is in Phase 2 for generalized anxiety disorder. These are neuroactive serotonergic molecules designed to be administered in a supervised clinical setting.

Full HELP guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• DFTX drivers: Late-stage psychiatry pipeline; Large unmet-need markets.
• HELP drivers: Phase 3 depression readout; Anxiety program optionality.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: As a pre-revenue clinical-stage company, Definium has no approved products and depends on trial outcomes, FDA decisions, and continued access to capital. For HELP, as a clinical-stage company, Helus has no revenue and posts ongoing net losses (about $171 million over the trailing twelve months as of October 2026), so it depends on trial success and repeated financing to survive.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick DFTX if you believe its drivers more; HELP if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the DFTX and HELP guides.

DFTX. Traditional valuation multiples do not apply because Definium has no revenue and reports net losses, with consensus looking for a loss of about $3.18 per share in 2026 and about $1.94 in 2027. The roughly $4.4 billion market value, about 4x the company's ~$1.08 billion cash pile, reflects expectations for DT120's approval and launch. The company has guided that its cash funds operations into 2028, and the next quarterly report is expected around November 5, 2026.

HELP. Standard earnings multiples do not apply because Helus has no revenue and runs at a loss while funding Phase 3 trials. At roughly $784 million, the market value is now well above the ~$166 million cash balance, so investors are assigning a substantial premium to the pipeline ahead of the Q4 2026 Phase 3 data, a bigger bet than earlier in the year. Valuation will hinge on trial outcomes and any resulting financing rather than on current financials.

Headline figures (approximate, October 2026): DFTX shows revenue (ttm) ~$0 (pre-revenue, no approved products), net loss (ttm) ~$354M (Q2 2026 alone ~$159M), eps (q2 2026 actual vs estimate) ~-$1.44 vs ~-$0.55, cash / debt (jun 2026) ~$1.08B / ~$36M; HELP shows share price ~$10.73 (Oct 16, 2026), market cap ~$784M, revenue (ttm) $0 (pre-revenue), net loss (ttm) ~$171M.

DFTX and HELP are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined DFTX and HELP exposure against your real portfolio. It is not an investment adviser.